Fig 1: Alterations in brain angiogenic factor under hypoxia and COX inhibition with ketorolac. Mice were treated with saline (1 and 2) or ketorolac (3 and 4) using osmotic pumps (s.c.) under 24-hr or 10-day normoxia (1 and 3, 20% O2) or hypoxia (2 and 4, 10% O2). Values are mean ± standard deviation (n (number of animals) =4) with individual values. Values that do not share the same letter are statistically different (p ? .05, one-way ANOVA with Tukey's post hoc test). (a) COX inhibition with ketorolac has no effect on HIF-1a levels under brain hypoxia as determined using ELISA. (b) COX inhibition with ketorolac has a slight but significant effect on brain VEGF and VEGFR2 levels under hypoxia. Brain VEGF was determined using ELISA. VEGFR2 were determined after western blot analysis and relative optical densities against actin are presented. Panels below bar graphs show representative blots for VEGFR2. (c). COX inhibition with ketorolac has no effect on brain bFGF and FGFR1 levels under hypoxia. Brain bFGF was determined using ELISA. pFGFR1 was determined after western blot analysis and relative optical densities against actin are presented. Panels below bar graphs show representative blots for pFGFR1. (d) COX inhibition with ketorolac has no effect on brain angiopoietin-2 under hypoxia. Brain angiopoietin-2 (Ang-2) was determined after western blot analysis and expressed as relative optical densities against actin. Panels below bar graphs show representative blots for Ang-2. (e) COX inhibition with ketorolac slightly but significantly attenuates CXCR4 after 10-day hypoxia. Brain CXCR4 was determined after western blot analysis and expressed as relative optical densities against actin. Panels below bar graphs show representative blots for CXCR4